MA48751B1 - Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax - Google Patents

Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Info

Publication number
MA48751B1
MA48751B1 MA48751A MA48751A MA48751B1 MA 48751 B1 MA48751 B1 MA 48751B1 MA 48751 A MA48751 A MA 48751A MA 48751 A MA48751 A MA 48751A MA 48751 B1 MA48751 B1 MA 48751B1
Authority
MA
Morocco
Prior art keywords
treatment
venetoclax
lymphoma
paradigm
antibody
Prior art date
Application number
MA48751A
Other languages
English (en)
Other versions
MA48751A (fr
Inventor
Mark Winderlich
Peter Kelemen
Michael Schwarz
Steffen Heeger
Dominika Weinelt
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA48751A publication Critical patent/MA48751A/fr
Publication of MA48751B1 publication Critical patent/MA48751B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La présente invention concerne des anticorps anti-cd19 et venetoclax destinés à être utilisés dans le traitement d'un lymphome non hodgkinien, d'une leucémie lymphoïde chronique et/ou d'un lymphome à petits lymphocytes. Les anticorps anti-cd19, en particulier mor00208, et le venetoclax sont administrés à des patients souffrant d'un lymphome non hodgkinien (lnh), d'une leucémie lymphocytaire chronique (llc) et/ou d'un lymphome à petits lymphocytes (lpl) selon un paradigme de traitement spécifique pour atténuer le syndrome de lyse tumorale associé à la thérapie.
MA48751A 2017-05-31 2018-05-30 Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax MA48751B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173712 2017-05-31
PCT/EP2018/064229 WO2018220040A1 (fr) 2017-05-31 2018-05-30 Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax

Publications (2)

Publication Number Publication Date
MA48751A MA48751A (fr) 2020-04-08
MA48751B1 true MA48751B1 (fr) 2023-11-30

Family

ID=59070416

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48751A MA48751B1 (fr) 2017-05-31 2018-05-30 Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Country Status (24)

Country Link
EP (2) EP4268900A3 (fr)
JP (2) JP7399713B2 (fr)
KR (1) KR20200010472A (fr)
CN (1) CN110678201A (fr)
AU (1) AU2018276384A1 (fr)
BR (1) BR112019025034A2 (fr)
CA (1) CA3062400A1 (fr)
DK (1) DK3630177T3 (fr)
ES (1) ES2961940T3 (fr)
FI (1) FI3630177T3 (fr)
HR (1) HRP20231229T1 (fr)
HU (1) HUE063119T2 (fr)
IL (2) IL297461A (fr)
LT (1) LT3630177T (fr)
MA (1) MA48751B1 (fr)
MD (1) MD3630177T2 (fr)
MX (1) MX2019014330A (fr)
PL (1) PL3630177T3 (fr)
PT (1) PT3630177T (fr)
RS (1) RS64746B1 (fr)
SG (1) SG11201909715VA (fr)
SI (1) SI3630177T1 (fr)
WO (1) WO2018220040A1 (fr)
ZA (1) ZA201907369B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203587A1 (fr) * 2020-11-30 2022-06-02 Incyte Corporation Polytherapie faisant appel a un anticorps anti-cd19 et a du parsaclisib
WO2022115120A1 (fr) * 2020-11-30 2022-06-02 Incyte Corporation Polythérapie comprenant un anticorps anti-cd19 et le parsaclisib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (fr) 2003-07-31 2009-01-21 Immunomedics Inc Anticorps anti-cd19
CA2611814A1 (fr) 2005-06-20 2007-01-04 Medarex, Inc. Anticorps cd19 et utilisations
CA2635623C (fr) 2005-12-30 2015-02-17 Michael Super Anticorps anti-cd19 d'immunogenicite reduite
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
AU2008311815B2 (en) 2007-10-19 2014-02-06 Seagen Inc. CD19 binding agents and uses thereof
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
RS63121B1 (sr) * 2011-08-16 2022-05-31 Morphosys Ag Kombinovana terapija sa anti-cd19 antitelom i analogom purina
US20140255427A1 (en) * 2011-08-16 2014-09-11 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
US11224654B2 (en) 2015-08-21 2022-01-18 Morphosys Ag Combinations and uses thereof
KR102500868B1 (ko) * 2016-10-28 2023-02-16 모르포시스 아게 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도

Also Published As

Publication number Publication date
HRP20231229T1 (hr) 2024-02-02
PT3630177T (pt) 2023-11-10
KR20200010472A (ko) 2020-01-30
JP7399713B2 (ja) 2023-12-18
CA3062400A1 (fr) 2018-12-06
LT3630177T (lt) 2023-10-25
IL270855B2 (en) 2023-03-01
IL270855B (en) 2022-11-01
HUE063119T2 (hu) 2024-01-28
JP2020521777A (ja) 2020-07-27
SG11201909715VA (en) 2019-11-28
ES2961940T3 (es) 2024-03-14
RU2019139552A (ru) 2021-07-01
RU2019139552A3 (fr) 2021-09-22
MA48751A (fr) 2020-04-08
SI3630177T1 (sl) 2023-12-29
MD3630177T2 (ro) 2024-01-31
DK3630177T3 (da) 2023-10-16
ZA201907369B (en) 2024-04-24
MX2019014330A (es) 2020-02-05
EP3630177A1 (fr) 2020-04-08
JP2024028865A (ja) 2024-03-05
WO2018220040A1 (fr) 2018-12-06
FI3630177T3 (fi) 2023-10-18
BR112019025034A2 (pt) 2020-06-30
EP4268900A2 (fr) 2023-11-01
PL3630177T3 (pl) 2024-04-08
RS64746B1 (sr) 2023-11-30
IL270855A (en) 2020-01-30
IL297461A (en) 2022-12-01
EP3630177B1 (fr) 2023-08-09
CN110678201A (zh) 2020-01-10
AU2018276384A1 (en) 2019-11-07
EP4268900A3 (fr) 2024-03-06

Similar Documents

Publication Publication Date Title
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
MA44146B1 (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA43075A1 (fr) Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA42020A1 (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA41717A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer ovarien épithélial et d'autres cancers
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA35180B1 (fr) Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA43466A1 (fr) Traitements du cancer de l'utérus
MA40094A1 (fr) Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
MA34753B1 (fr) Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes
MA40621B1 (fr) Traitement de la fibrodysplasie ossifiante progressive
ATE530577T1 (de) Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
MA38478A1 (fr) Anticorps anti-pac1 humains
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
MA43794B1 (fr) Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA43477A1 (fr) Immunothérapie contre le mélanome et d'autres cancers
MA48751B1 (fr) Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax